Johnson & Johnson (NYSE:JNJ) Issues Quarterly Earnings Results

Johnson & Johnson (NYSE:JNJ) released its earnings results on Wednesday. The company reported $2.46 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $2.46, FiscalAI reports. The company had revenue of $24.56 billion during the quarter, compared to analyst estimates of $24.14 billion. Johnson & Johnson had a return on equity of 33.34% and a net margin of 28.46%.The company’s revenue for the quarter was up 9.1% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.04 earnings per share. Johnson & Johnson updated its FY 2026 guidance to 11.430-11.630 EPS.

Here are the key takeaways from Johnson & Johnson’s conference call:

• Johnson & Johnson reported a very strong 2025 (FY sales of $94.2B, Q4 sales $24.6B) and issued 2026 guidance calling for ~5.7%–6.7% operational sales growth with a midpoint near $100B and adjusted EPS guidance centered around $11.28–$11.48 (reported ~ $11.53 at midpoint).
• Innovative Medicine is driving momentum — oncology grew rapidly (21% in 2025) with Darzalex topping ~$14B, Carvykti has treated >10,000 patients, Tecvayli showed very strong phase‑3 results, and immunology leader Tremfya accelerated (Q4 +65%) and passed $5B in 2025 with a path to >$10B.
• MedTech transformation is advancing with ~$34B in 2025 sales, strong performances from Abiomed and Shockwave, commercial traction for VARIPULSE, and strategic regulatory progress including the Ottava De Novo submission and planned Monarch urology robotics launch that underpin future growth.
• Material legal and cost headwinds remain — the talc MDL produced a mixed Daubert report that J&J will appeal, litigation costs rose (noted ~$0.9B), and near‑term P&L pressures include elevated tariffs (≈$500M guidance for 2026) plus a higher diluted share count (~2.44B shares) that creates EPS headwinds and ongoing uncertainty.

Johnson & Johnson Stock Performance

Shares of NYSE:JNJ opened at $218.58 on Friday. The company has a market capitalization of $526.62 billion, a price-to-earnings ratio of 19.78, a P/E/G ratio of 2.24 and a beta of 0.34. The firm’s 50 day simple moving average is $207.86 and its 200 day simple moving average is $188.48. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.07 and a quick ratio of 0.80. Johnson & Johnson has a fifty-two week low of $141.50 and a fifty-two week high of $222.17.

Johnson & Johnson Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Tuesday, February 24th will be paid a $1.30 dividend. The ex-dividend date of this dividend is Tuesday, February 24th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.4%. Johnson & Johnson’s dividend payout ratio is 50.19%.

Key Stories Impacting Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Q4 print and 2026 outlook: J&J beat revenue expectations, reported stronger margins and gave FY2026 sales and EPS guidance that was modestly above consensus — the core drivers cited were oncology strength and MedTech momentum. This underpins the bullish analyst reaction and higher expectations for organic growth. Business Wire: Q4 and Full-Year 2025 results
• Positive Sentiment: Large analyst upgrade: Scotiabank boosted its price target sharply to $265 (sector outperform), signaling meaningful upside versus the current level and likely supporting buying interest. The Fly: Scotiabank price-target raise
• Positive Sentiment: Technical/market momentum: MarketBeat highlights a trend-following buy signal after the pullback to support levels, which can attract momentum traders and reduce downside risk for buyers. MarketBeat: trend-following buy signal
• Neutral Sentiment: Analyst tweaks with limited conviction: Bank of America and Stifel nudged targets higher (to $221 and $220 respectively) but kept neutral/hold stances — these adjustments offer modest upside but little change to conviction. Benzinga: analyst target changes
• Positive Sentiment: Dividend and longer-term thesis remain intact: Coverage pieces note J&J’s status as a Dividend King with a sustainable payout and a growing MedTech pipeline (including OTTAVA robotics), supporting steady institutional demand. Zacks: dividend thesis
• Negative Sentiment: Talc litigation moving forward: A court ruling will allow plaintiffs’ expert testimony in the talc MDL, increasing legal uncertainty and potential exposure that remains an overhang for the stock. Benzinga: talc litigation update
• Negative Sentiment: Stelara biosimilar pressure: Investors remain cautious after Stelara sales fell sharply following patent loss; biosimilar competition is dragging growth in that franchise and was cited as a reason for pre-market weakness even after the beat. Blockonomi: Stelara and market reaction

Hedge Funds Weigh In On Johnson & Johnson

Several institutional investors have recently modified their holdings of JNJ. Brighton Jones LLC raised its stake in shares of Johnson & Johnson by 13.9% in the 4th quarter. Brighton Jones LLC now owns 51,876 shares of the company’s stock valued at $7,502,000 after purchasing an additional 6,332 shares during the period. United Bank grew its stake in shares of Johnson & Johnson by 110.7% during the 1st quarter. United Bank now owns 9,279 shares of the company’s stock worth $1,539,000 after acquiring an additional 4,876 shares in the last quarter. Sivia Capital Partners LLC raised its holdings in shares of Johnson & Johnson by 13.4% in the second quarter. Sivia Capital Partners LLC now owns 5,863 shares of the company’s stock valued at $896,000 after purchasing an additional 692 shares during the last quarter. Wealth Group Ltd. boosted its holdings in Johnson & Johnson by 12.8% during the second quarter. Wealth Group Ltd. now owns 1,482 shares of the company’s stock worth $226,000 after purchasing an additional 168 shares during the last quarter. Finally, Schnieders Capital Management LLC. grew its position in Johnson & Johnson by 9.8% in the second quarter. Schnieders Capital Management LLC. now owns 73,680 shares of the company’s stock valued at $11,255,000 after purchasing an additional 6,584 shares in the last quarter. Institutional investors own 69.55% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on the stock. Scotiabank reissued an “outperform” rating on shares of Johnson & Johnson in a research note on Thursday. Weiss Ratings reissued a “buy (b)” rating on shares of Johnson & Johnson in a report on Friday, October 31st. Morgan Stanley upped their target price on Johnson & Johnson from $197.00 to $200.00 and gave the stock an “equal weight” rating in a research report on Thursday. Bank of America lifted their target price on shares of Johnson & Johnson from $220.00 to $221.00 and gave the company a “neutral” rating in a research report on Thursday. Finally, Royal Bank Of Canada set a $240.00 price target on shares of Johnson & Johnson in a research note on Wednesday, December 17th. Two research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and nine have assigned a Hold rating to the stock. According to MarketBeat.com, Johnson & Johnson has a consensus rating of “Moderate Buy” and a consensus price target of $219.86.

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.